2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Robert Dreicer, MD, from the Taussig Cancer Institute, Discusses How New Treatments Have Improved Survival
Robert Dreicer, MD from the Taussig Cancer Institute, explains that the survival benefits observed for abiraterone acetate (Zytiga) and sipuleucel-T (Provenge) are both in the range of 4 months. Additionally, post docetaxel the agent cabazitaxel also improves survival. Since all of these agents improve survival the questions becomes how do you use them, should you combine, and in which population.